CX 1739

Drug Profile

CX 1739

Alternative Names: CX-1739

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; National Institute on Drug Abuse; RespireRx Pharmaceuticals
  • Class Antidementias; Mood stabilisers; Respiratory stimulants
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory insufficiency; Sleep apnoea syndrome
  • Preclinical Drug abuse
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 08 Jan 2018 RespireRx intends to file an IND, and initiate a phase II trial investigating the ability of CX 1739 to reduce central sleep apnoea in patients taking chronic opioids
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Sleep-apnoea-syndrome(Combination therapy) in USA (PO, Capsule)
  • 06 Sep 2017 RespirRx plans a clinical trial in Respiratory insufficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top